

# Leukocytes carrying *Clonal Hematopoiesis of Indeterminate Potential (CHIP)* Mutations invade Human Atherosclerotic Plaques

**Short title: CHIP in atherosclerotic plaque**

Moritz von Scheidt<sup>1,2</sup>, Sabine Bauer<sup>1,2</sup>, Angela Ma<sup>3</sup>, Ke Hao<sup>3</sup>, Thorsten Kessler<sup>1,2</sup>, Baiba Vilne<sup>2,4,5</sup>, Ying Wang<sup>6</sup>, Chani J. Hodonsky<sup>7</sup>, Saikat K.B. Ghosh<sup>8</sup>, Michal Mokry<sup>9,10</sup>, Hua Gao<sup>11</sup>, Kenji Kawai<sup>8</sup>, Atsushi Sakamoto<sup>8,12</sup>, Juliane Kaiser<sup>13</sup>, Dario Bongiovanni<sup>14,15</sup>, Julia Fleig<sup>1</sup>, Lilith Oldenbuettel<sup>1</sup>, Zhifen Chen<sup>1,2</sup>, Aldo Moggio<sup>1,2</sup>, Hendrik B. Sager<sup>1,2</sup>, Judith S. Hecker<sup>16</sup>, Florian Bassermann<sup>16</sup>, Lars Maegdefessel<sup>2,17</sup>, Clint L. Miller<sup>18</sup>, Wolfgang Koenig<sup>1,2</sup>, Andreas M. Zeiher<sup>19</sup>, Stefanie Dimmeler<sup>19</sup>, Matthias Graw<sup>13</sup>, Christian Braun<sup>13</sup>, Arno Ruusalepp<sup>20,21,22</sup>, Nicholas J. Leeper<sup>10,23</sup>, Jason C. Kovacic<sup>24,25,26</sup>, Johan L.M. Björkegren<sup>\*3,21,27</sup>, Heribert Schunkert<sup>\*1,2</sup>

\*Authors contributed equally

## Affiliations

1 Department of Cardiology, German Heart Center Munich, Technical University Munich, Munich, Germany.

2 Deutsches Zentrum für Herz- und Kreislaufforschung (DZHK), Partner Site Munich Heart Alliance, Munich, Germany.

3 Department of Genetics and Genomic Sciences, Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, USA.

4 Bioinformatics Lab, Riga Stradiņš University, Riga, Latvia.

5 SIA Net-OMICS, Riga, Latvia.

6 Department of Pathology and Laboratory Medicine, Centre for Heart Lung Innovation, University of British Columbia, Vancouver, Canada.

7 Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA.

8 CVPPath Institute, Inc, Gaithersburg, USA.

9 Laboratory of Experimental Cardiology, Department of Cardiology, University Medical Center Utrecht, University Utrecht, Utrecht, Netherlands.

10 Central Diagnostics Laboratory, University Medical Center Utrecht, Utrecht, The Netherlands

11 Division of Vascular Surgery, Department of Surgery, Stanford University School of Medicine, Stanford, USA.

12 Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan.

13 Institute of Legal Medicine, Faculty of Medicine, LMU Munich, Germany.

14 Department of Internal Medicine I, Cardiology, University Hospital Augsburg, University of Augsburg, Germany.

15 Department of Cardiovascular Medicine, Humanitas Clinical and Research Center IRCCS and Humanitas University, Rozzano, Milan, Italy.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

16 Department of Medicine III, Technical University of Munich (TUM), Klinikum rechts der Isar, Munich, Germany.

17 Department for Vascular and Endovascular Surgery, Klinikum Rechts der Isar, Technical University Munich, Munich, Germany.

18 Center for Public Health Genomics, Department of Public Health Sciences, Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, USA.

19 Institute for Cardiovascular Regeneration, Goethe University Frankfurt am Main, Frankfurt am Main, Germany.

20 Department of Cardiac Surgery, The Heart Clinic, Tartu University Hospital, Tartu, Estonia.

21 Clinical Gene Networks AB, Stockholm, Sweden.

22 Institute of Clinical Medicine, Faculty of Medicine, Tartu University, Tartu, Estonia.

23 Stanford Cardiovascular Institute, Stanford University, Stanford, USA.

24 Victor Chang Cardiac Research Institute, Darlinghurst, Australia.

25 St. Vincent's Clinical School, University of New South Wales, Sydney, Australia.

26 Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, USA.

27 Department of Medicine, Huddinge, Karolinska Institutet, Karolinska Universitetssjukhuset, Stockholm, Sweden.

### **Corresponding authors**

Prof. Dr. med. Heribert Schunkert, MD; ORCID 0000-0001-6428-3001 and

Dr. Dr. med. Moritz von Scheidt, MD; ORCID 0000-0001-7159-8271

Deutsches Herzzentrum München (German Heart Center Munich)

Klinik für Herz- und Kreislauferkrankungen

Lazarettstr. 36

D-80636 München

Telephone: +49-89-1218-2849

Fax: +49-89-1218-4013

Email: [schunkert@dhm.mhn.de](mailto:schunkert@dhm.mhn.de); [moritz.scheidt@tum.de](mailto:moritz.scheidt@tum.de);

### **Total word count**

9,590 (including Title Page, Abstract, Text, References, Tables and Figure Legends)

1 **Background:** Leukocyte progenitors derived from clonal hematopoiesis of undetermined  
2 potential (CHIP) are associated with increased cardiovascular events. However, the  
3 prevalence and functional relevance of CHIP in coronary artery disease (CAD) are unclear,  
4 and cells affected by CHIP have not been detected in human atherosclerotic plaques.

5 **Methods:** CHIP mutations in blood and tissues were identified by targeted deep-DNA-  
6 sequencing (DNAseq: coverage >3,000) and whole-genome-sequencing (WGS: coverage  
7 >35). CHIP-mutated leukocytes were visualized in human atherosclerotic plaques by  
8 MutaFISH™. Functional relevance of CHIP mutations was studied by RNAseq.

9 **Results:** DNAseq of whole blood from 540 deceased CAD patients of the Munich  
10 Cardiovascular Studies Biobank (MISSION) identified 253 (46.9%) CHIP mutation carriers  
11 (mean age 78.3 years). DNAseq on myocardium, atherosclerotic coronary and carotid arteries  
12 detected identical CHIP mutations in 18 out of 25 mutation carriers in tissue DNA. MutaFISH™  
13 visualized individual macrophages carrying *DNMT3A* CHIP mutations in human atherosclerotic  
14 plaques. Studying monocyte-derived macrophages from Stockholm-Tartu Atherosclerosis  
15 Reverse Networks Engineering Task (STARNET; n=941) by WGS revealed CHIP mutations  
16 in 14.2% (mean age 67.1 years). RNAseq of these macrophages revealed that expression  
17 patterns in CHIP mutation carriers differed substantially from those of non-carriers. Moreover,  
18 patterns were different depending on the underlying mutations, e.g. those carrying *TET2*  
19 mutations predominantly displayed upregulated inflammatory signaling whereas *ASXL1*  
20 mutations showed stronger effects on metabolic pathways.

21 **Conclusions:** Deep-DNA-sequencing reveals a high prevalence of CHIP mutations in whole  
22 blood of CAD patients. CHIP-affected leukocytes invade plaques in human coronary arteries.  
23 RNAseq data obtained from macrophages of CHIP-affected patients suggest that pro-  
24 atherosclerotic signaling differs depending on the underlying mutations. Further studies are  
25 necessary to understand whether specific pathways affected by CHIP mutations may be  
26 targeted for personalized treatment.

27 **Key words:** aging, atherosclerotic cardiovascular disease, clonal hematopoiesis of  
28 indeterminate potential, coronary artery disease, inflammation

## 29 Introduction

30 Clonal hematopoiesis of undetermined potential (CHIP) is a common age-related condition  
31 and potential precursor to hematological neoplasms. CHIP is defined as presence of a clonally  
32 expanded hematopoietic cell caused by a somatic mutation in individuals without hematologic  
33 abnormalities. Such mutations, predominantly in the epigenetic regulators *DNMT3A*, *TET2* or  
34 *ASXL1*, have been identified in bone marrow and blood, but these cells have never been  
35 definitively detected in human atherosclerotic plaques.<sup>1</sup> Whole-exome sequencing has shown  
36 that CHIP is practically absent in individuals younger than 30 years of age, whereas it is  
37 present in 20% to 30% of individuals aged 50 to 60 years.<sup>1, 2</sup> The use of more sensitive  
38 sequencing techniques and access to bone marrow has demonstrated that small clones are  
39 quite common in middle-aged individuals.<sup>3, 4</sup> CHIP carriers have an increased risk of  
40 cardiovascular events and mortality, including early onset and aggravated progression of  
41 coronary artery disease (CAD), myocardial infarction, stroke, aortic valve calcification and  
42 chronic ischemic heart failure.<sup>5-8</sup> The higher the burden of CHIP-affected cells measured by  
43 the variant allele frequency (VAF), the higher was the reported risk of adverse events.<sup>5-8</sup>  
44 Indeed, detection of CHIP in peripheral blood may serve as a biomarker for adverse outcomes  
45 in individuals with cardiovascular diseases (CVDs).

46 Experimental studies deciphered the first mechanistic insights explaining the associations of  
47 CHIP mutations with CVD. Fuster et al. demonstrated that transplantation of bone marrow  
48 containing a *Tet2* loss-of-function mutation in hematopoietic cells in mice mimics the human  
49 situation of CHIP including increased numbers of activated macrophages (measured by  
50 upregulation of *IL-1 $\beta$* ) found in plaques. Aggravated atherosclerosis was triggered by activation  
51 of the inflammatory cascade in these cells. Further, *in-vitro* LPS-stimulation of macrophages  
52 carrying somatic mutations led to increased expression of *IL-6*, the downstream mediator of  
53 the inflammasome complex, and *IL-1 $\beta$* .<sup>9</sup>

54 Our current understanding is that driver mutations in *DNMT3A*, *TET2* or *ASXL1* lead to  
55 expansion of clones in the bone marrow resulting in increased numbers of cells with epigenetic  
56 alterations in the peripheral blood. These changes result in increased expression of genes  
57 associated with inflammatory pathways, which in turn may stimulate the progression of  
58 atherosclerosis.<sup>10</sup> Here we studied the prevalence of CHIP in DNA sequence data, whether  
59 CHIP-mutated leukocytes invade atherosclerotic plaques in human arteries and whether  
60 macrophages isolated from CAD patients carrying specific CHIP mutations also present with  
61 specific CAD signatures by examining macrophage RNA-expression profiles and associated  
62 clinical phenotypes (**Figure 1**).

## 63 **Materials and Methods**

### 64 **Ethics approval**

65 The institutional review board and Ethics Committee of the Technical University of Munich,  
66 Germany, approved the protocol of MISSION (2018-325-S-KK – 08/22/2018). The use of  
67 human STARNET samples has been approved by the Estonian Bioethics and Human  
68 Research Committee (Ministry of Social Affairs) (IRB 2771T,17 – 12/01/2018) and by the  
69 written informed consent of the donor, in accordance with the guidelines and regulations for  
70 the use of biological material of human origin. Both studies were conducted in accordance with  
71 the provisions of the Declaration of Helsinki and the International Conference on  
72 Harmonization guidelines for good clinical practice.

### 73 **Data accessibility**

74 Data used in this study are available in permanent repositories. Human data from MISSION  
75 can be requested by qualified researchers at the German Heart Center Munich from the  
76 corresponding author. Human data from STARNET are accessible through the Database of  
77 Genotypes and Phenotypes (dbGAP).

### 78 **MISSION – cohort and sample description**

79 The Munich cardioVascular Studies biObaNk (MISSION) was started in 2019 and comprises  
80 cardiovascular relevant tissues, including blood and plasma, liver, myocardium, coronary, and  
81 carotid samples from >950 deceased individuals sampled in FFPE and fresh frozen at -80°C.  
82 Prior to freezing and sequencing, all tissues are washed and subsequently conserved in  
83 PBS/DMSO. MISSION provides the full spectrum of coronary phenotypes from healthy to  
84 severe atherosclerosis. DNA of leukocytes and cardiovascular tissues was analyzed by deep-  
85 targeted-amplicon-sequencing. The leukocytes derived from whole blood, and the analyzed  
86 tissue encompassed the proximal part of atherosclerosis-affected left anterior descending  
87 (LAD) coronary, atherosclerosis-affected left carotid artery and left ventricular heart muscle.

## 88 **DNA extraction from blood and tissue**

89 For the extraction of DNA from whole blood, the Maxwell DNA Blood Kit (Promega) was used.  
90 For this purpose, whole blood was incubated for 20 minutes at room temperature under rotation  
91 (Rotating shaker, Kisker Biotech, Germany). Then, 300µl of whole blood was mixed with 300µl  
92 of lysis buffer and 30µl of proteinase K. The mixture was incubated under rotation for 30  
93 minutes at room temperature, followed by another 30 minutes at 65°C and 600rpm in a heat  
94 block (Thermomixer comfort, Eppendorf, Germany). Every 10 minutes, incubation was  
95 performed at 1500rpm for approximately 1 minute. DNA extraction from human coronary  
96 artery, carotid and left ventricle was performed based on 50mg of frozen tissue samples.  
97 Perivascular tissue was removed from arteries and tissues were washed in 1x PBS. Isolation  
98 was performed based on a modified Maxwell DNA Blood kit (Promega) protocol. After  
99 mechanical homogenization (TissueLyser II, Qiagen, The Netherlands) of the tissues in 300µl  
100 incubation buffer, 1-thioglycerol and proteinase K were added. The mixture was incubated for  
101 4 hours at 65°C and 600rpm in a heat block (Thermomixer comfort, Eppendorf, Germany).  
102 This was followed by the addition of 300µl of lysis buffer and re-incubation for 10 minutes at  
103 600rpm. Finally, the batches (blood and tissue) were transferred to the first well of the cartridge  
104 included in the kit. After addition of the plunger, the cartridge was inserted into the Maxwell  
105 RSC 48 system. The supplied elution tubes (0.5ml) were filled with 65µl of elution buffer and  
106 also inserted into the instrument. Finally, the predefined Maxwell DNA Blood protocol was  
107 selected and DNA was isolated in around 37 minutes. Isolated DNA was measured  
108 fluorometrically with a Qubit 3.0 (ThermoScientific).

## 109 **Sample preparation and DNA extraction**

110 Whole blood and cardiovascular tissues were analyzed by deep-DNA-sequencing to detect  
111 hematopoietic stem cell derived mononuclear cells with CHIP mutations in cardiovascular  
112 relevant tissues. Samples were sequenced using an Illumina TruSeq Custom sequencing  
113 panel at the Munich Leukemia Laboratory. The concentration of extracted genomic DNA was  
114 determined with a Qubit dsDNA HS assay kit (Life Technologies) and then diluted to 25ng/µl



115 in 30µl of nuclease free water. A depth of more than 1000 detections per gene was targeted  
116 for sequencing to reliably detect CHIP-mutated hematopoietic cells in whole blood,  
117 atherosclerosis-affected coronary and carotid artery, and myocardium of the left ventricle.

### 118 **Deep-DNA-sequencing**

119 A previously established panel containing 594 amplicons in 56 genes was used in the Illumina  
120 TruSeq Custom Amplicon Low Input assay.<sup>6</sup> To allow improved identification of low allele  
121 frequency variants, double-strand sequencing was performed. In addition, 6-bp unique  
122 molecular identifiers (UMIs) were included in the target-specific primers. Prior to sequencing,  
123 pooled libraries were diluted and denatured according to the NextSeq System Denature and  
124 Dilute Libraries Guide (Illumina). 1% PhiX DNA was added. Pooled libraries were sequenced  
125 with the NextSeq 500 sequencer (Illumina) using the NextSeq 500/550 Mid Output, Version 2  
126 kit (300 cycles) according to the manufacturer's instructions. The sequencer was run in paired-  
127 end sequencing mode with a read length of 2x150bp and an index read length of 2x8bp. The  
128 BCL files were demultiplexed and converted to FASTQ files using the FASTQ Generation tool  
129 on BaseSpace (Illumina). The average coverage of the samples was >3,000 per gene. The  
130 variants were further validated on the basis of being reported in the literature and/or the  
131 Catalogue of Somatic Mutations in Cancer (<https://cancer.sanger.ac.uk/cosmic>) and ClinVar  
132 (<https://www.ncbi.nlm.nih.gov/clinvar>). The 56 gene panel was adapted after screening the first  
133 n=192 individuals to a custom 13 gene panel comprising *ASXL1*, *CALR*, *CBL*, *DNMT3A*, *JAK2*,  
134 *MPL*, *PPM1D*, *SF3B1*, *SRSF2*, *TET2*, *TP53*, *U2AF1* and *ZRSR2*, thereby covering almost 90%  
135 of known CHIP mutations. The 13 gene panel followed the same analysis pipeline.

### 136 **Visualization of specific CHIP mutations in human plaques**

137 Mutation specific Fluorescence In Situ Hybridization (mutaFISH™) analysis on *DNMT3A* gene  
138 was performed on 3-5µm thick tissue sections from human coronary and carotid arteries of  
139 patients with known mutation (c.2245C>T and c.2333T>G) in the *DNMT3A* gene. In situ rolling  
140 circle technology was performed using custom made dual color *DNMT3A* mutation and

141 wildtype specific FISH probes (Abnova, Taiwan). The detailed protocol used for pretreatment,  
142 reverse transcription, hybridization, amplification and signal detection is provided in the  
143 supplement. It is based on the manufacturers protocol for mutaFISH™ RNA Accessory Kit and  
144 the protocol for muta FISH™ HER2wt RNA probes with some modifications in target retrieval,  
145 washing buffer and incubation. Negative controls were used to establish unspecific binding  
146 and background. All reagents were prepared with RNase free (DEPC treated) water/PBS. For  
147 hybridization a Boekel Scientific Slide Moat oven was used. Images were acquired at the  
148 ZEISS Axioscan 7 slide scanner and analysis was performed using Zeiss Software ZEN 3.5  
149 blue edition.

## 150 **STARNET – Study and sample description**

151 To further study the ability of CHIP-mutated leukocytes to invade atherosclerotic plaques and  
152 to identify their biological impact we leveraged the Stockholm-Tartu Atherosclerosis Reverse  
153 Networks Engineering Task (STARNET) study datasets. Briefly, patients with CAD undergoing  
154 coronary artery bypass grafting (CABG; n=941) donated multiple tissue samples that included  
155 liver, skeletal muscle, subcutaneous fat, visceral abdominal fat, atherosclerotic aortic wall,  
156 internal mammary artery and whole blood as previously described.<sup>11</sup> After quality control, WGS  
157 data of all 941 STARNET individuals were suitable for downstream CHIP analysis.

## 158 **Whole genome sequencing**

159 DNA from whole blood was isolated with the QIAmp DNA Blood Midi kit (Qiagen). DNA  
160 qualities were assessed with the Agilent 2100 Bioanalyzer system (Agilent Technologies, Palo  
161 Alto, CA). Library preparation and sequencing were performed at Beijing Genomic Institute  
162 (BGI). Genomic DNA samples that passed quality control were randomly fragmented by  
163 Covaris technology and 350bp fragments were selected. End repair of DNA fragments was  
164 performed and an "A" base was added at the 3'-end of each strand. Adapters were then ligated  
165 to both ends of the end repaired/dA tailed DNA fragments and amplified by ligation-mediated  
166 PCR (LM-PCR), followed by single strand separation and cyclization. Rolling circle

167 amplification was performed to produce DNA Nanoballs (DNBs). The qualified DNBs were  
168 loaded into patterned nanoarrays and pair-end reads were read through on the BGISEQ-500  
169 platform. High-throughput sequencing was performed for each library to ensure that each  
170 sample met the average sequencing coverage requirement of 35x. Sequencing-derived raw  
171 image files were processed by BGISEQ-500 base-calling software with default parameters,  
172 and the sequence data of each individual was generated as paired-end reads.

173 Raw data in FASTQ format was filtered and raw reads with low quality were removed. Data  
174 was aligned to the human reference genome (GRCh37/HG19) by Burrows-Wheeler Aligner  
175 (BWA) v0.7.12<sup>12, 13</sup> and variant calling was performed by Genome Analysis Toolkit (v3.3.0)<sup>14</sup>  
176 with duplicate reads removed by Picard tools v1.118.<sup>15</sup>

177 The HaplotypeCaller of GATK was used to call both SNPs and InDels simultaneously via local  
178 de-novo assembly of haplotypes in a region showing signs of variation.<sup>16, 17</sup> Base quality scores  
179 were recalibrated using GATK BaseRecalibrator and SNPs recalibration was performed using  
180 GATK VariantRecalibrator function.<sup>18, 19</sup>

### 181 **CHIP somatic variant identification and validation**

182 Heterozygous missense, nonsense, InDel and splicing variants of one or two base pairs in  
183 coding regions of CHIP-associated genes including *ASXL1*, *TET2*, *JAK2*, and *DNMT3A* were  
184 identified by filtering data from vcf files according to: 1) genotype quality > 30; 2) minor allele  
185 frequency <1% in 1000 genome database; 3) minor allele frequency <1% in the cohort.

186 Variant analysis in RNAseq data in blood, aorta, liver, skeletal muscle, subcutaneous fat,  
187 visceral abdominal fat, monocyte derived macrophages and macrophage derived foam cells  
188 from STARNET subjects was performed for identification and validation of somatic mutations  
189 identified via whole genome sequencing. Because bone marrow or hematopoietic cells that  
190 carry somatic mutations could present in leukocytes in whole blood, in atherosclerotic plaques  
191 in the diseased aorta, or in macrophages and foam cells isolated and differentiated from whole  
192 blood, variants that presented in at least one of these four tissues/cell types but not in any

193 other tissues (liver, skeletal muscle, subcutaneous fat, visceral abdominal fat) were defined as  
194 somatic mutations.

## 195 **RNA sequencing and data processing**

196 The effects of CHIP mutations on gene expression were studied in macrophages and foam  
197 cells. After centrifugation of whole blood, the cell pellet was washed with 1x PBS and cells  
198 were plated. After 3-6 hours, the monocytes adhered to the plate and non-adherent  
199 erythrocytes and lymphocytes could be washed off during adhesion purification. The  
200 monocytes were subsequently cultured in human serum, stimulated and differentiated into  
201 macrophages over 48-72 hours. The transition to foam cells was achieved by treatment with  
202 oxidized low-density lipoprotein (LDL) cholesterol. Finally, the macrophages and foam cells  
203 were harvested and RNA was isolated.<sup>11</sup>

204 RNA library preparation was based on the Ribo-Zero library preparation method using Illumina  
205 TruSeq nonstranded mRNA kit. Samples were randomized to prevent batch effects.  
206 Sequencing was performed with paired-end reads of 100 base pairs on an Illumina HiSeq, and  
207 quality control was performed using FASTQC3. GENCODE was used to quantify the  
208 expression of genes and isoforms and mapped to the human genome using STAR4. The  
209 average coverage was >40 million reads per sample. Only samples with more than 1 million  
210 unambiguously assigned reads were used for further analysis.

## 211 **Genetics, imputation and eQTL analysis**

212 Genetic data were analyzed on a genome build 37 background using GenomeStudio  
213 (Illumina). After genetic sex confirmation, quality control was performed using PLINK v 2.05.  
214 Data were imputed using the HRC r1.1 2016 reference panel using minimac4. Cis- and trans-  
215 regulated expression quantitative trait loci (eQTLs) in macrophages were determined using R  
216 package matrix eQTL v.2.1.1. Adjustments were made for age, sex, BMI and the first five  
217 genetic principal components. Cis-regulatory SNPs within 1 megabase of the respective gene

218 were determined by a linear regression model (hg19 genomes). An FDR <5% was considered  
219 statistically significant.

## 220 **Differential gene expression and pathway analysis**

221 Differences in gene expression between CHIP mutation carriers and controls were investigated  
222 using the R package limma. Covariates in the linear regression model were age, sex and BMI.  
223 Adjusted p-values <0.05 were considered statistically significant. Differentially expressed  
224 genes were analyzed for overrepresentation of genes from genome-wide association studies  
225 (GWAS) to CAD using PhenoScanner. Differentially expressed genes were analyzed by  
226 binomial test for enrichment of Gene Ontology (GO) terms and by Gene Set Enrichment  
227 Analysis (GSEA). The maximum size of a gene set in GSEA was set to 3,000. Bonferroni-  
228 corrected p-values <0.05 were considered statistically significant.

## 229 **Network and Key Driver Analysis**

230 Regulatory networks were reconstructed using GENIE3, based on a random forests ensemble  
231 method.<sup>20</sup> The network was enriched with transcription factors and cis-eQTL-regulated genes  
232 from macrophages as candidate regulators.<sup>21, 22</sup> Weighted key driver analysis (wKDA) was  
233 performed using mergeomics.<sup>23, 24</sup> Mergeomics allows disease-relevant processes to be  
234 mapped onto molecular interaction networks in order to identify hubs as potential key  
235 regulators. The network visualization was realized with Cytoscape v3.7.0.

## 236 **Co-expression modules and association with clinical traits**

237 Correlation patterns between gene expression were analyzed using R package Weighted  
238 Gene Co-expression Network Analysis (WGCNA) to construct correlation networks and  
239 identify co-expression modules. Correlations of gene expression with clinical traits were  
240 calculated using Spearman correlation. The association of co-expression modules with clinical  
241 traits was analyzed using Fisher's exact test to calculate the enrichment of the number of  
242 significantly correlated genes in each module.

## 243 Results

### 244 CHIP screening by deep DNA sequencing

245 In MISSION, a total of 540 individuals who died at an age between 40 to 98 years old (mean  
246 age 75.1 years) were found to have CAD at autopsy. These subjects were screened for CHIP  
247 mutations with a mean sequencing depth of 3,592-fold, with at least 1,000-fold per gene. A  
248 total of 253 individuals (46.9%) carried 445 individual CHIP mutations in whole blood. The  
249 prevalence of CHIP mutations increased with age ( $R=0.76$ ;  $p<0.001$ ), the mean age of  
250 mutation carriers was 78.3 years and 113 (44.7%) were female. 78 individuals carried at least  
251 one CHIP mutation with a VAF  $>10\%$ , 130 individuals carried at least one CHIP mutation with  
252 a VAF  $>2\%$  and 45 individuals were identified with clonal hematopoiesis with a VAF  $<2\%$   
253 (**Supplemental Figure 1**). The greatest burden of CHIP was found in an 85-year-old man who  
254 carried 6 unique mutations. Most somatic mutations were identified in *DNMT3A* (155  
255 mutations), *TET2* (152) and *ASXL1* (32). Further, CHIP mutations were detected in *BCOR*,  
256 *CBL*, *CALR*, *CBL*, *EZH2*, *GNAS*, *GNB1*, *IDH1*, *JAK2*, *KRAS*, *PPM1D*, *RAD21*, *SETBP1*,  
257 *SF3B1*, *SMC1A*, *SMC3*, *SRSF2*, *TP53*, *U2AF1* and *ZRSR2* (**Supplemental Table 1**).

258 The presence of CHIP mutations in cardiovascular tissues was studied on DNA level in a  
259 subset of 25 confirmed CHIP mutation carriers. Specifically, we looked for respective mutations  
260 in atherosclerosis-affected coronary and carotid arteries, and myocardium of the left ventricle.  
261 Samples with VAF between 0.5% and 30.0% were analyzed. 18 identical CHIP mutations (i.e.  
262 in 72.0% of cases) were identified in at least one corresponding tissue, whereas no *de novo*  
263 mutation was detected on tissue level – serving as internal quality control. In 13 (52.0%)  
264 atherosclerosis-affected samples of the proximal left anterior descending (LAD) coronary  
265 artery CHIP mutations were retrieved: *DNMT3A* (5 mutations), *TET2* (4), *ASXL1* (1), *CBL* (1),  
266 *PPM1D* (1), and *SMC3* (1). In atherosclerosis-affected carotid artery samples 10 mutations in  
267 *DNMT3A* (6 mutations), *TET2* (3) and *PPM1D* (1) were identified, as well as 4 in the  
268 myocardium of the left ventricle of atherosclerosis-affected individuals in *DNMT3A* (1), *TET2*

269 (2) and *SMC3* (1). In general, leukocytes are the only DNA-containing cells in whole blood. In  
270 arterial tissue, various cells - e.g. smooth muscle cells, endothelial cells, leukocytes - carry  
271 DNA. Given the low proportion of leukocytes in atherosclerotic arterial tissue, an enrichment  
272 of CHIP-affected leukocytes - as identified for *PPM1D* - is likely in plaques (**Table 1**,  
273 **Supplemental Figure 2**).

#### 274 **Visualization of specific CHIP mutations**

275 To further detect and visualize specific point mutations of interest on RNA level in single cells  
276 custom made mutaFISH™ probes (Abnova, Taiwan) were designed.<sup>25, 26</sup> The targeted  
277 *DNMT3A* mutations c.2245T>C and c.2333G>T, initially identified in whole blood of CAD  
278 patients, were identified in leukocytes of the corresponding mutation carriers in human  
279 atherosclerotic plaque (**Figure 2**). For optimal orientation, all arterial samples were also  
280 stained for hematoxylin and eosin (HE) and Elastin van Gieson (EvG) (**Supplemental Figure**  
281 **3**). Further, staining for CD68 revealed that CHIP-affected leukocytes in these cases could be  
282 identified as macrophages (**Supplemental Figure 4**). CHIP-mutated macrophages were  
283 mainly identified in the shoulder regions of advanced and inflammation rich plaques of human  
284 coronary and carotid samples (**Figure 2, Supplemental Figure 4+5**).

#### 285 **CHIP screening by WGS**

286 The 941 patients of the STARNET study undergoing open heart surgery were younger (65.9  
287 years) and WGS sequencing had a lower depth (35-fold) than deep-DNAseq carried out in  
288 MISSION.<sup>11</sup> Overall, 159 specific CHIP mutations in the genes *ASXL1*, *DNMT3A*, *JAK2* or  
289 *TET2* were identified in 134 (14.2%) individuals in STARNET (**Supplemental Table 2**). Mean  
290 age of these CHIP mutation carriers was 67.1 years and 27 (17.0%) were female. 51 CHIP  
291 mutations could be confidentially replicated on RNA level in at least one tissue. Variant analysis  
292 in RNAseq data confirmed the CHIP mutations at the RNA level in whole blood (43 mutations),  
293 monocyte derived cultured macrophages (10 mutations) and cultured macrophage derived  
294 foam cells (5), as well as in atherosclerosis-affected aortic tissue (18) of CAD patients.

## 295 **CHIP in macrophages**

296 To study the effects of CHIP mutations on gene expression in macrophages we grouped  
297 individuals carrying *TET2* and *ASXL1* mutations and compared these to age- and sex-matched  
298 non-mutation carriers (controls). Most macrophages (>80%) belonged to the M0 subtype.

## 299 **Differential gene expression analysis of TET2-mutated macrophages**

300 Mean age of *TET2* CHIP mutation carriers (n=3; c.6819G>T; c.6834C>T and c.7698T>C) and  
301 matched controls (n=21) showed no significant difference (60.3±12.0 vs 61.8±8.2 years).  
302 Detailed information on patient characteristics can be found in **Supplemental Table 3**. In total,  
303 1,523 genes were differentially expressed in *TET2* mutation carriers compared to controls.  
304 1,098 genes were upregulated and 425 genes were downregulated in CHIP mutation carriers.  
305 Top upregulated genes were *LINC01882*, *IGKV3-15*, *IGHG2* and *IGHA1*, top downregulated  
306 genes were *BMS1P10* and *ZCCHC4* ( $p_{adj.} < 0.05$ ).

307 GO analysis revealed as top enriched GO terms T cell receptor complex (GO:0042101),  
308 opsonization (GO:0008228) and immune response by circulating immunoglobulin  
309 (GO:0002455). In general, immune system and inflammation associated pathways were  
310 upregulated (**Figure 3**).

311 Weighted Gene Co-expression Network Analysis (WGCNA) was used to establish co-  
312 expression modules based on macrophage RNAseq data from STARNET, to identify functional  
313 relations between genes, and based on genetic regulatory networks (GRN) to identify key  
314 driver genes. A total of 23 modules were generated from 10,267 transcripts with module sizes  
315 ranging between 36 to 2473 genes using the complete macrophage RNAseq data from  
316 STARNET. The gene functions of the co-expression modules were analyzed using GO terms.  
317 *TET2* mutations in macrophages led to significant perturbation in the darkgreen module  
318 ( $p < 0.001$ ), which consists of 38 genes and is primarily involved in immune system related  
319 pathways (GO:0019814, GO:0003823, GO:0006959, GO:0006958, GO:0002455,



320 GO:0006956, GO:0002768, GO:0002764, GO:0016064, GO:0019724; all  $p < 0.001$ ). Most  
321 relevant key driver genes in this module were *BACH2*, *BANK1*, *BLK*, *FCRL3*, *MS4A1* and  
322 *PAX5*. Significant associations were identified for the presence of severity and complexity of  
323 CAD based on coronary angiograms, measured by SYNTAX score (**Figure 3**).

#### 324 **Differential gene expression analysis of ASXL1-mutated macrophages**

325 After matching, mean age of *ASXL1* CHIP mutation carriers ( $n=3$ ; c.2331C>T; c.4890A>G and  
326 c.5137G>A) and controls ( $n=27$ ) showed no significant difference ( $67.3 \pm 5.5$  vs  $67.3 \pm 5.6$   
327 years). Detailed information on patient characteristics can be found in **Supplemental Table 4**.  
328 In macrophages of *ASXL1* CHIP mutation carriers 1,222 genes were differentially expressed  
329 compared to controls. 665 genes were upregulated and 557 genes were downregulated in  
330 CHIP mutation carriers. Top upregulated genes were *HLA-DQB2*, *ASNS* and *SLC25A16*, top  
331 downregulated genes were *NP1PB2*, *HNRNPH1* and *POLA2* ( $p_{\text{adj.}} < 0.05$ ). GO analysis revealed  
332 intracellular anatomical structure (GO:0005622), RNA binding (GO:0003723) and heterocyclic  
333 compound binding (GO:1901363) as top enriched terms. *ASXL1* mutations led to upregulation  
334 of cell cycle and metabolic process associated pathways (**Figure 4**).

335 *ASXL1* mutations in macrophages led to significant perturbation in the black module ( $p < 0.001$ ),  
336 which consists of 468 genes and is involved in the *intracellular translation of RNA into proteins*  
337 (GO:0022626, GO:0006614, GO:0019083, GO:0006613, GO:0045047, GO:0006413,  
338 GO:0072599, GO:0000184, GO:0019080, GO:0070972; all  $p < 0.001$ ). Most relevant key driver  
339 genes in the black module were *ANAPC16*, *CZIB*, *RPL7A*, *RPL14* and *SNHG6*. The black  
340 module was significantly associated with cardiometabolic relevant traits including low-density  
341 lipoprotein (LDL) and total cholesterol plasma levels, blood glucose and BMI, inflammation  
342 measured by plasma C-reactive protein (CRP) levels, and with the presence and complexity  
343 of coronary lesions (**Figure 4**).

#### 344 **Discussion**

345 To further explore the role of CHIP mutations in CAD, we carried out large-scale, targeted  
346 deep-sequencing of genes prone to cause clonal hematopoiesis in MISSION, one of the largest  
347 postmortem biobanks focusing on cardiovascular disease. We found at least one characteristic  
348 mutation in about 46% of individuals who died with CAD at an average age of 78 years,  
349 highlighting that CHIP mutations were significantly more common in CAD patients than  
350 previously reported for subjects with unknown CAD status.<sup>2, 5, 27, 28</sup>

351 In about 70% of affected individuals, the same mutation could be detected within  
352 cardiovascular tissues, either in DNA or – in case of coding variants – around one third in RNA.  
353 Albeit the cellular composition is different in blood and various tissues, a similar percentage of  
354 cells carrying CHIP mutations was found in respective samples. Exemplary visualization of two  
355 different *DNMT3A* mutations was achieved within macrophages residing in atherosclerotic  
356 human coronary and carotid arteries by in situ fluorescent staining. CHIP mutations, which are  
357 thought to promote the development and progression of ischemic heart failure,<sup>6, 29, 30</sup> were also  
358 detected in left ventricular myocardial samples of CAD patients.

359 The implications of CHIP mutations were then investigated using the STARNET datasets,  
360 focusing on CAD patients undergoing open heart surgery (average age 67 years).<sup>11, 31</sup> Based  
361 on whole-genome sequencing and RNAseq data – carried out at a lower depth than the  
362 targeted deep-sequencing in MISSION – CHIP mutations were found in about 14% of CAD  
363 patients, who most likely represented higher VAFs in affected individuals. Mutations were also  
364 detected in aortic samples affected by atherosclerosis, monocyte-derived macrophages, and  
365 foam cells. This allowed us to further study the implications of CHIP mutations with respect to  
366 clinical presentations and RNA expression patterns.

367 RNA sequencing revealed large numbers of differentially expressed genes in macrophages of  
368 CHIP mutation carriers – as compared to patients free of these mutations. Interestingly,  
369 patterns of gene expression also differed between those having mutations in *TET2* and *ASXL1*,  
370 i.e. two of the most prominent CHIP mutations.

371 Patients carrying *TET2*-mutations had a higher CAD burden and – as measured by SYNTAX  
372 score – more complex CAD. Macrophages generated *in vitro* by transformation of monocytes  
373 from these patients revealed multiple differentially expressed genes. Enrichment analysis  
374 revealed upregulation of immune system and inflammation associated pathways. Specifically,  
375 *TET2* mutations related to perturbation of a small atherosclerosis relevant macrophage gene  
376 expression network with most relevant key driver genes being *BACH2*, *BANK1*, *BLK*, *FCRL3*,  
377 *MS4A1* and *PAX5* mainly involved in immune response, cell migration and leukocyte  
378 differentiation.

379 *ASXL1* CHIP mutation carriers revealed upregulation of cardiometabolic relevant traits  
380 including low-density lipoprotein (LDL) cholesterol plasma levels, inflammation measured by  
381 plasma C-reactive protein (CRP) levels, and – like *TET2* mutations – a higher prevalence and  
382 complexity of CAD. In macrophages, *ASXL1* CHIP mutations revealed differentially expressed  
383 genes, of note inflammasome related genes were upregulated. Enrichment analysis of  
384 differentially expressed genes revealed that *ASXL1* mutations related to perturbations of  
385 pathways associated with cell cycle and metabolic processes. Top key drivers affected by  
386 CHIP mutations were *ANAPC16*, *CZIB*, *RPL7A*, *RPL14* and *SNHG6* mainly involved in  
387 regulation of metabolic processes, ubiquitination and protein synthesis.

388 Given the relevance of inflammation and cardiovascular conditions that have been associated  
389 with CHIP, there appears to be an opportunity to treat selected patients with specific anti-  
390 inflammatory strategies,<sup>32-34</sup> for example, by targeting the *NLRP3* inflammasome, *IL-1 $\beta$*  or *IL-*  
391 *6* with agents like canakinumab (monoclonal antibody against *IL-1 $\beta$* ),<sup>35</sup> anakinra (an *IL-1 $\beta$*   
392 receptor antagonist),<sup>36-39</sup> tocilizumab (monoclonal antibody against the *IL-6* receptor),<sup>40, 41</sup>  
393 ziltevekimab (anti-*IL-6* ligand monoclonal antibody),<sup>42</sup> or colchicine.<sup>43-45</sup> Interestingly, an  
394 exploratory retrospective analysis of the CANTOS trial that studied the effects of canakinumab  
395 in patients with an acute coronary syndrome suggested increased inflammatory activation and  
396 more cardiovascular events, as well as specific treatment benefits in carriers of CHIP-  
397 mutations. However, the value of this analysis is limited as only 40% of the initial CANTOS

398 population was screened for CHIP mutations such that the overall number of CHIP mutation  
399 carriers was low.<sup>46</sup> Our study supports the concept that specific CHIP mutations might identify  
400 subgroups of patients with explicit alterations in gene expression in various cardiovascular  
401 relevant tissues – mainly stimulating pro-inflammatory mechanisms – which might be relevant  
402 in the future for directing specific treatments to these individuals.

### 403 **Limitations**

404 Our study has several limitations. Firstly, as we have no longitudinal data, it is unclear how  
405 long individual CHIP mutations have been present. CHIP mutations are acquired over decades  
406 and their related risks may grow over time. However, the exact time of acquisition of CHIP  
407 mutations is difficult to determine and unknown in most cases. Secondly, the limited depth of  
408 WGS in STARNET and the focused CHIP screening panel in MISSION may have left mutation  
409 carriers undetected. Overlooking CHIP mutation carriers in STARNET may have impaired our  
410 sensitivity to discriminate their related effects on clinical and transcriptional characteristics.  
411 Thirdly, different DNA sequencing platforms have different levels of coverage, specificity and  
412 sensitivity, making it difficult to compare results from different platforms. Standardization of  
413 sequencing methods and analysis pipelines would be desirable to ensure comparability of  
414 results and improve the accuracy of CHIP screening in the future. Fourth, the relevance of  
415 respective mutations and the quantitative burden of VAFs need further clarification. The VAF  
416 of CHIP mutations is an essential factor in determining their biological significance, but there  
417 is a limited knowledge of optimal VAF ‘cut-offs’ for individual CHIP mutations. Yet, high VAF  
418 has been associated with an increased risk of cardiovascular events. In chronic ischemic heart  
419 failure (CHF), individual clone size thresholds of less than 2% in *DNMT3A* and *TET2* have  
420 already been associated with worse outcomes.<sup>29</sup> It remains to be clarified which VAF threshold  
421 is relevant for individual CHIP mutations and specific phenotypes, and whether these could  
422 serve as novel biomarkers or support treatment decisions. Fifth, the relevance of respective  
423 mutations in one or the other gene, including the additive effects of multiple mutations needs  
424 further investigation. An essential key for future personalized therapy approaches will be to

425 validate these CHIP related outcomes in well-powered, prospective RCTs. Finally, the local  
426 effects of individual CHIP-mutated macrophages residing within cardiovascular tissues needs  
427 spatial investigation.

## 428 **Conclusions**

429 Our data highlight that blood derived circulating CHIP-affected leukocytes have the potential  
430 to invade human atherosclerotic lesions in coronary and carotid arteries, aorta, and heart  
431 muscle. We visualized CHIP-mutated leukocytes with single cell resolution in human  
432 atherosclerotic plaques and staining confirmed these leukocytes as CD68<sup>+</sup> macrophages.  
433 Since these acquired CHIP mutations originate from hematopoietic stem or progenitor cells in  
434 the bone marrow and were identified in whole blood, the visualized CHIP mutations cannot  
435 originate from resident arterial macrophages. Further, RNA sequencing identified CHIP  
436 specific signatures in macrophages, novel key regulators and associations with clinical traits  
437 like burden and complexity of CAD (**Figure 1**). Future studies are needed to further  
438 characterize underlying molecular mechanisms by which individual mutations contribute to  
439 CVDs and whether targeting specific pathways may be valuable for precision medicine in  
440 patients carrying mutations encoding for CHIP.

441 **Novelty and Significance**

442 **What is known? (2-3 bullet points)**

- 443 - CHIP represents an independent risk factor for the onset and progression of  
444 cardiovascular diseases and death
- 445 - CHIP mutations are associated with inflammatory activation of circulating monocytes  
446 and T-cells
- 447 - Individual CHIP mutations could be important as biomarkers in the future and help  
448 identify high-risk patients suitable for anti-inflammatory therapy

449 **What new information does this article contribute? (max. 200 words)**

450 Our work provides insights on three open questions in the field. Firstly, we provide higher  
451 estimates of the proportion of CAD patients affected by CHIP mutations, if these are studied  
452 by focused deep-sequencing in whole blood. Next, we show that CHIP-mutated leukocytes  
453 have the potential to invade human plaques and thereby contribute locally to atherosclerosis.  
454 Specifically, we visualized macrophages at single cell resolution by a specific *DNMT3A* CHIP  
455 mutations probe in coronary plaques. We also identified blood derived CHIP mutations in  
456 human coronary and carotid arteries and heart muscle on DNA level. Additionally, we describe  
457 previously unknown key-regulatory genes and pro-atherosclerotic alterations at the RNA level  
458 of CHIP mutated macrophages. Importantly, different CHIP mutations appear to affect different  
459 pathways, networks and modules, which nevertheless all have relevance for CAD progression.  
460 These novel results (**Figure 1**) appear to be of relevance for future personalized medicine  
461 approaches specifically designed for CHIP mutation carriers.

## 462 **Acknowledgments**

463 M.v.S drafted the manuscript, designed and coordinated the study. J.K., M.G. and C.B.  
464 provided human cardiovascular tissues in MISSION. M.v.S, S.B., J.F., D.B. and L.O.  
465 performed the CHIP screening in MISSION. S.B. performed the mutaFISH™ experiment. A.M.,  
466 K.H., A.R., J.C.K. and J.L.M.B. contributed data from STARNET. Y.W., C.J.H., S.K.B.G., M.M.,  
467 H.G., K.K., A.S., C.M., N.L., J.L.M.B. and H.S. provided relevant intellectual input within the  
468 Leducq PlaqOmics Consortium. B.V., T.K., Z.C., A.M., H.B.S. and L.M. were involved RNAseq  
469 analyses. J.S.H., F.B. and W.K. provided relevant intellectual input regarding hematological  
470 aspects and biomarkers. A.M.Z. and S.D. supported within the joint DZHK CHIP moonshot  
471 project. All authors critically reviewed the manuscript and agreed with the final version of the  
472 manuscript, written by M.v.S. J.L.M.B. and H.S.. Special thanks for scientific support to the  
473 Munich Leukemia Laboratory (MLL), Germany. Illustrations contain image material available  
474 at Servier Medical Art under a creative commons attribution 3.0 unported license.

## 475 **Sources of Funding**

476 This study was funded by the German Center for Cardiovascular Research (DZHK), Berlin,  
477 Germany, (DZHK81X2200145 and DZHK-81X2600520). M.v.S. is supported by an excellence  
478 grant of the German Center for Cardiovascular Research (DZHK-81X3600506), the German  
479 Heart Foundation (Deutsche Herzstiftung e.V.), and a Junior Research Group Cardiovascular  
480 Diseases Grant of the CORONA Foundation (S199/10085/2021). M.v.S., Y.W., C.J.H.,  
481 S.K.B.G., M.M., H.G., K.K., A.S. and A.A. are supported by a Leducq PlaqOmics Junior  
482 Investigator Grant. This work was further supported by grants from the Fondation Leducq  
483 (PlaqOmics), the Bavarian State Ministry of Health and Care through the research project  
484 DigiMed Bayern ([www.digimed-bayern.de](http://www.digimed-bayern.de)), the Bavarian State Ministry of Science and the Arts  
485 through the research project Deutsches Herzzentrum München and Munich School of Robotics  
486 and Machine learning Joint Research Center, the German Federal Ministry of Education and  
487 Research within the framework of European Research Area Network on Cardiovascular

488 Disease. J.C.K. acknowledges research support from the National Institutes of Health  
489 (R01HL148167), New South Wales health grant RG194194, the Bourne Foundation and  
490 Agilent. J.L.M.B. acknowledges support from the Swedish Research Council (2018-02529 and  
491 2022-00734), the Swedish Heart Lung Foundation (2017-0265 and 2020-0207), the Leducq  
492 Foundation AteroGen (22CVD04) and PlaqOmics (18CVD02) consortia; the National Institute  
493 of Health-National Heart Lung Blood Institute (NIH/NHLBI, R01HL164577; R01HL148167;  
494 R01HL148239, R01HL166428, and R01HL168174), American Heart Association  
495 Transformational Project Award 19TPA34910021, and from the CMD AMP fNIH program.

496 **Disclosures**

497 None.



## 498 References

- 499 1. Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoun SF,  
500 Chambert K, Mick E, Neale BM, Fromer M, Purcell SM, Svantesson O, Landen M, Hoglund  
501 M, Lehmann S, Gabriel SB, Moran JL, Lander ES, Sullivan PF, Sklar P, Gronberg H,  
502 Hultman CM and McCarroll SA. Clonal hematopoiesis and blood-cancer risk inferred from  
503 blood DNA sequence. *N Engl J Med.* 2014;371:2477-87.
- 504 2. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC,  
505 Mermel CH, Burt N, Chavez A, Higgins JM, Moltchanov V, Kuo FC, Kluk MJ, Henderson B,  
506 Kinnunen L, Koistinen HA, Ladenvall C, Getz G, Correa A, Banahan BF, Gabriel S,  
507 Kathiresan S, Stringham HM, McCarthy MI, Boehnke M, Tuomilehto J, Haiman C, Groop L,  
508 Atzmon G, Wilson JG, Neuberg D, Altshuler D and Ebert BL. Age-related clonal  
509 hematopoiesis associated with adverse outcomes. *N Engl J Med.* 2014;371:2488-98.
- 510 3. Young AL, Challen GA, Birman BM and Druley TE. Clonal haematopoiesis  
511 harbouring AML-associated mutations is ubiquitous in healthy adults. *Nat Commun.*  
512 2016;7:12484.
- 513 4. Hecker JS, Hartmann L, Riviere J, Buck MC, van der Garde M, Rothenberg-Thurley  
514 M, Fischer L, Winter S, Ksienzyk B, Ziemann F, Solovey M, Rauner M, Tsourdi E, Sockel K,  
515 Schneider M, Kubasch AS, Nolde M, Hausmann D, Paulus AC, Lutzner J, Roth A,  
516 Bassermann F, Spiekermann K, Marr C, Hofbauer LC, Platzbecker U, Metzeler KH and  
517 Gotze KS. CHIP and hips: clonal hematopoiesis is common in patients undergoing hip  
518 arthroplasty and is associated with autoimmune disease. *Blood.* 2021;138:1727-1732.
- 519 5. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M,  
520 Gupta N, Gabriel S, Ardissino D, Baber U, Mehran R, Fuster V, Danesh J, Frossard P,  
521 Saleheen D, Melander O, Sukhova GK, Neuberg D, Libby P, Kathiresan S and Ebert BL.  
522 Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. *N Engl J Med.*  
523 2017;377:111-121.
- 524 6. Dorsheimer L, Assmus B, Rasper T, Ortmann CA, Ecke A, Abou-El-Ardat K, Schmid  
525 T, Brune B, Wagner S, Serve H, Hoffmann J, Seeger F, Dimmeler S, Zeiher AM and Rieger  
526 MA. Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in  
527 Chronic Ischemic Heart Failure. *JAMA Cardiol.* 2019;4:25-33.
- 528 7. Bhattacharya R, Zekavat SM, Haessler J, Fornage M, Raffield L, Uddin MM, Bick AG,  
529 Niroula A, Yu B, Gibson C, Griffin G, Morrison AC, Psaty BM, Longstreth WT, Bis JC, Rich  
530 SS, Rotter JI, Tracy RP, Correa A, Seshadri S, Johnson A, Collins JM, Hayden KM, Madsen  
531 TE, Ballantyne CM, Jaiswal S, Ebert BL, Kooperberg C, Manson JE, Whitsel EA, Program  
532 NT-OfPM, Natarajan P and Reiner AP. Clonal Hematopoiesis Is Associated With Higher Risk  
533 of Stroke. *Stroke.* 2022;53:788-797.
- 534 8. Gumuser ED, Schuermans A, Cho SMJ, Sporn ZA, Uddin MM, Paruchuri K, Nakao T,  
535 Yu Z, Haidermota S, Hornsby W, Weeks LD, Niroula A, Jaiswal S, Libby P, Ebert BL, Bick  
536 AG, Natarajan P and Honigberg MC. Clonal Hematopoiesis of Indeterminate Potential  
537 Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease. *J Am*  
538 *Coll Cardiol.* 2023;81:1996-2009.
- 539 9. Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R,  
540 Wu CL, Sano S, Muralidharan S, Rius C, Vuong J, Jacob S, Muralidhar V, Robertson AA,  
541 Cooper MA, Andres V, Hirschi KK, Martin KA and Walsh K. Clonal hematopoiesis associated  
542 with TET2 deficiency accelerates atherosclerosis development in mice. *Science.*  
543 2017;355:842-847.
- 544 10. Libby P and Ebert BL. CHIP (Clonal Hematopoiesis of Indeterminate Potential):  
545 Potent and Newly Recognized Contributor to Cardiovascular Risk. *Circulation.* 2018;138:666-  
546 668.
- 547 11. Koplev S, Seldin S, Sukhvasi K, Ermel R, Pang S, Zeng L, Bankier S, Di Narzo A,  
548 Cheng H, Meda V, Ma A, Talukdar H, Cohain A, Amadori L, Argmann C, Houten S, Franzén  
549 O, Mocchi G, Meelu O, Ishikawa K, Whatling C, Jain A, Jain R, Gan L, Giannarelli C, Roussos  
550 P, Hao K, Schunkert H, Michael T, Ruusalepp A, Schadt E, Kovacic J, Lusis A and  
551 Björkegren J. A mechanistic framework for cardiometabolic and coronary artery diseases.  
552 *Nature Cardiovascular Research.* 2022;1:85–100.

- 553 12. Li H and Durbin R. Fast and accurate short read alignment with Burrows-Wheeler  
554 transform. *Bioinformatics*. 2009;25:1754-60.
- 555 13. Li H and Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler  
556 transform. *Bioinformatics*. 2010;26:589-95.
- 557 14. Nowak J, Koscińska K, Mika-Witkowska R, Rogatko-Koros M, Mizia S, Jaskula E,  
558 Polak M, Mordak-Domagala M, Lange J, Gronkowska A, Jedrzejczak WW, Kyrz-Krzemien  
559 S, Markiewicz M, Dzierzak-Mietla M, Tomaszewska A, Nasilowska-Adamska B, Szczepinski  
560 A, Halaburda K, Hellmann A, Komarnicki M, Gil L, Czyz A, Wachowiak J, Baranska M,  
561 Kowalczyk J, Drabko K, Gozdzik J, Wysoczanska B, Bogunia-Kubik K, Graczyk-Pol E,  
562 Witkowska A, Marosz-Rudnicka A, Nestorowicz K, Dziopa J, Szlendak U, Warzocha K and  
563 Lange AA. Donor NK cell licensing in control of malignancy in hematopoietic stem cell  
564 transplant recipients. *Am J Hematol*. 2014;89:E176-83.
- 565 15. Broadinstitute. Picard. 2022;2022:Picard v1.118.
- 566 16. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella  
567 K, Altshuler D, Gabriel S, Daly M and DePristo MA. The Genome Analysis Toolkit: a  
568 MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res*.  
569 2010;20:1297-303.
- 570 17. Poplin R, Ruano-Rubio V, DePristo MA, Fennell TJ, Carneiro MO, Van der Auwera  
571 GA, Kling DE, Gauthier LD, Levy-Moonshine A, Roazen D, Shakir K, Thibault J, Chandran S,  
572 Whelan C, Lek M, Gabriel S, Daly MJ, Neale B, MacArthur DG and Banks E. Scaling  
573 accurate genetic variant discovery to tens of thousands of samples. *bioRxiv*. 2018:201178.
- 574 18. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA,  
575 del Angel G, Rivas MA, Hanna M, McKenna A, Fennell TJ, Kernytsky AM, Sivachenko AY,  
576 Cibulskis K, Gabriel SB, Altshuler D and Daly MJ. A framework for variation discovery and  
577 genotyping using next-generation DNA sequencing data. *Nat Genet*. 2011;43:491-8.
- 578 19. Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine  
579 A, Jordan T, Shakir K, Roazen D, Thibault J, Banks E, Garimella KV, Altshuler D, Gabriel S  
580 and DePristo MA. From FastQ data to high confidence variant calls: the Genome Analysis  
581 Toolkit best practices pipeline. *Curr Protoc Bioinformatics*. 2013;43:11 10 1-11 10 33.
- 582 20. Huynh-Thu VA and Geurts P. dynGENIE3: dynamical GENIE3 for the inference of  
583 gene networks from time series expression data. *Sci Rep*. 2018;8:3384.
- 584 21. Lizio M, Harshbarger J, Shimoji H, Severin J, Kasukawa T, Sahin S, Abugessaisa I,  
585 Fukuda S, Hori F, Ishikawa-Kato S, Mungall CJ, Arner E, Baillie JK, Bertin N, Bono H, de  
586 Hoon M, Diehl AD, Dimont E, Freeman TC, Fujieda K, Hide W, Kaliyaperumal R, Katayama  
587 T, Lassmann T, Meehan TF, Nishikata K, Ono H, Rehli M, Sandelin A, Schultes EA, t Hoen  
588 PA, Tatum Z, Thompson M, Toyoda T, Wright DW, Daub CO, Itoh M, Carninci P,  
589 Hayashizaki Y, Forrest AR, Kawaji H and consortium F. Gateways to the FANTOM5  
590 promoter level mammalian expression atlas. *Genome Biol*. 2015;16:22.
- 591 22. Abugessaisa I, Ramilowski JA, Lizio M, Severin J, Hasegawa A, Harshbarger J,  
592 Kondo A, Noguchi S, Yip CW, Ooi JLC, Tagami M, Hori F, Agrawal S, Hon CC, Cardon M,  
593 Ikeda S, Ono H, Bono H, Kato M, Hashimoto K, Bonetti A, Kato M, Kobayashi N, Shin J, de  
594 Hoon M, Hayashizaki Y, Carninci P, Kawaji H and Kasukawa T. FANTOM enters 20th year:  
595 expansion of transcriptomic atlases and functional annotation of non-coding RNAs. *Nucleic  
596 Acids Res*. 2021;49:D892-D898.
- 597 23. Shu L, Zhao Y, Kurt Z, Byars SG, Tukiainen T, Kettunen J, Orozco LD, Pellegrini M,  
598 Lusi AJ, Ripatti S, Zhang B, Inouye M, Makinen VP and Yang X. Mergeomics:  
599 multidimensional data integration to identify pathogenic perturbations to biological systems.  
600 *BMC Genomics*. 2016;17:874.
- 601 24. Ding J, Blencowe M, Nghiem T, Ha SM, Chen YW, Li G and Yang X. Mergeomics 2.0:  
602 a web server for multi-omics data integration to elucidate disease networks and predict  
603 therapeutics. *Nucleic Acids Res*. 2021;49:W375-W387.
- 604 25. Larsson C, Grundberg I, Soderberg O and Nilsson M. In situ detection and  
605 genotyping of individual mRNA molecules. *Nat Methods*. 2010;7:395-7.
- 606 26. Larsson C, Koch J, Nygren A, Janssen G, Raap AK, Landegren U and Nilsson M. In  
607 situ genotyping individual DNA molecules by target-primed rolling-circle amplification of  
608 padlock probes. *Nat Methods*. 2004;1:227-32.

- 609 27. Yu Z, Fidler TP, Ruan Y, Vlasschaert C, Nakao T, Uddin MM, Mack T, Niroula A,  
610 Heimlich JB, Zekavat SM, Gibson CJ, Griffin GK, Wang Y, Peloso GM, Heard-Costa N, Levy  
611 D, Vasani RS, Aguet F, Ardlie K, Taylor KD, Rich SS, Rotter JI, Libby P, Jaiswal S, Ebert BL,  
612 Bick AG, Tall AR and Natarajan P. Genetic modification of inflammation and clonal  
613 hematopoiesis-associated coronary artery disease. *medRxiv*. 2022:2022.12.08.22283237.  
614 28. Jaiswal S and Libby P. Clonal haematopoiesis: connecting ageing and inflammation  
615 in cardiovascular disease. *Nat Rev Cardiol*. 2020;17:137-144.  
616 29. Assmus B, Cremer S, Kirschbaum K, Culmann D, Kiefer K, Dorsheimer L, Rasper T,  
617 Abou-El-Ardat K, Herrmann E, Berkowitsch A, Hoffmann J, Seeger F, Mas-Peiro S, Rieger  
618 MA, Dimmeler S and Zeiher AM. Clonal haematopoiesis in chronic ischaemic heart failure:  
619 prognostic role of clone size for DNMT3A- and TET2-driver gene mutations. *Eur Heart J*.  
620 2021;42:257-265.  
621 30. Pascual-Figal DA, Bayes-Genis A, Diez-Diez M, Hernandez-Vicente A, Vazquez-  
622 Andres D, de la Barrera J, Vazquez E, Quintas A, Zuriaga MA, Asensio-Lopez MC, Dopazo  
623 A, Sanchez-Cabo F and Fuster JJ. Clonal Hematopoiesis and Risk of Progression of Heart  
624 Failure With Reduced Left Ventricular Ejection Fraction. *J Am Coll Cardiol*. 2021;77:1747-  
625 1759.  
626 31. Franzen O, Ermel R, Cohain A, Akers NK, Di Narzo A, Talukdar HA, Foroughi-Asl H,  
627 Giambartolomei C, Fullard JF, Sukhvasi K, Koks S, Gan LM, Giannarelli C, Kovacic JC,  
628 Betsholtz C, Losic B, Michoel T, Hao K, Roussos P, Skogsberg J, Ruusalepp A, Schadt EE  
629 and Bjorkegren JL. Cardiometabolic risk loci share downstream cis- and trans-gene  
630 regulation across tissues and diseases. *Science*. 2016;353:827-30.  
631 32. Tall AR and Bornfeldt KE. Inflammasomes and Atherosclerosis: a Mixed Picture. *Circ*  
632 *Res*. 2023;132:1505-1520.  
633 33. Hettwer J, Hinterdobler J, Miritsch B, Deutsch MA, Li X, Mauersberger C, Moggio A,  
634 Braster Q, Gram H, Robertson AAB, Cooper MA, Gross O, Krane M, Weber C, Koenig W,  
635 Soehnlein O, Adamstein NH, Ridker P, Schunkert H, Libby P, Kessler T and Sager HB.  
636 Interleukin-1beta suppression dampens inflammatory leucocyte production and uptake in  
637 atherosclerosis. *Cardiovasc Res*. 2022;118:2778-2791.  
638 34. Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW and Dinarello CA.  
639 Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. *Circ*  
640 *Res*. 2020;126:1260-1280.  
641 35. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C,  
642 Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D,  
643 Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M,  
644 Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ and  
645 Group CT. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *N Engl*  
646 *J Med*. 2017;377:1119-1131.  
647 36. Abbate A, Trankle CR, Buckley LF, Lipinski MJ, Appleton D, Kadariya D, Canada JM,  
648 Carbone S, Roberts CS, Abouzaki N, Melchior R, Christopher S, Turlington J, Mueller G,  
649 Garnett J, Thomas C, Markley R, Wohlford GF, Puckett L, Medina de Chazal H, Chiabrando  
650 JG, Bressi E, Del Buono MG, Schatz A, Vo C, Dixon DL, Biondi-Zoccai GG, Kontos MC and  
651 Van Tassell BW. Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in  
652 Patients With ST-Segment-Elevation Myocardial Infarction. *J Am Heart Assoc*.  
653 2020;9:e014941.  
654 37. Buckley LF and Abbate A. Interleukin-1 blockade in cardiovascular diseases: a  
655 clinical update. *Eur Heart J*. 2018;39:2063-2069.  
656 38. Dragoljevic D, Lee MKS, Louis C, Shihata W, Kraakman MJ, Hansen J, Masters SL,  
657 Hanaoka BY, Nagareddy PR, Lancaster GI, Wicks IP and Murphy AJ. Inhibition of  
658 interleukin-1beta signalling promotes atherosclerotic lesion remodelling in mice with  
659 inflammatory arthritis. *Clin Transl Immunology*. 2020;9:e1206.  
660 39. Ku EJ, Kim BR, Lee JI, Lee YK, Oh TJ, Jang HC and Choi SH. The Anti-  
661 Atherosclerosis Effect of Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist,  
662 in Apolipoprotein E Knockout Mice. *Int J Mol Sci*. 2022;23.

- 663 40. Hartman J and Frishman WH. Inflammation and atherosclerosis: a review of the role  
664 of interleukin-6 in the development of atherosclerosis and the potential for targeted drug  
665 therapy. *Cardiol Rev.* 2014;22:147-51.
- 666 41. Poznyak AV, Bharadwaj D, Prasad G, Grechko AV, Sazonova MA and Orekhov AN.  
667 Anti-Inflammatory Therapy for Atherosclerosis: Focusing on Cytokines. *Int J Mol Sci.*  
668 2021;22.
- 669 42. Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, Lo  
670 L, Kling D, Pergola P, Raj D, Libby P, Davidson M and Investigators R. IL-6 inhibition with  
671 ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised,  
672 placebo-controlled, phase 2 trial. *Lancet.* 2021;397:2060-2069.
- 673 43. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim  
674 R, Gamra H, Kiwan GS, Berry C, Lopez-Sendon J, Ostadal P, Koenig W, Angoulvant D,  
675 Gregoire JC, Lavoie MA, Dube MP, Rhainds D, Provencher M, Blondeau L, Orfanos A,  
676 L'Allier PL, Guertin MC and Roubille F. Efficacy and Safety of Low-Dose Colchicine after  
677 Myocardial Infarction. *N Engl J Med.* 2019;381:2497-2505.
- 678 44. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu  
679 XF, Ireland MA, Lenderink T, Latchem D, Hoogslag P, Jerzewski A, Nierop P, Whelan A,  
680 Hendriks R, Swart H, Schaap J, Kuijper AFM, van Hessen MWJ, Saklani P, Tan I, Thompson  
681 AG, Morton A, Judkins C, Bax WA, Dirksen M, Alings M, Hankey GJ, Budgeon CA, Tijssen  
682 JGP, Cornel JH, Thompson PL and LoDoCo2 Trial I. Colchicine in Patients with Chronic  
683 Coronary Disease. *N Engl J Med.* 2020;383:1838-1847.
- 684 45. Opstal TSJ, van Broekhoven A, Fiolet ATL, Mosterd A, Eikelboom JW, Nidorf SM,  
685 Thompson PL, Budgeon CA, Bartels L, de Nooijer R, Bax WA, Tijssen JGP, El Messaoudi S  
686 and Cornel JH. Long-Term Efficacy of Colchicine in Patients With Chronic Coronary Disease:  
687 Insights From LoDoCo2. *Circulation.* 2022;145:626-628.
- 688 46. Svensson EC, Madar A, Campbell CD, He Y, Sultan M, Healey ML, Xu H, D'Aco K,  
689 Fernandez A, Wache-Mainier C, Libby P, Ridker PM, Beste MT and Basson CT. TET2-  
690 Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the  
691 CANTOS Randomized Clinical Trial. *JAMA Cardiol.* 2022;7:521-528.

692 **Tables**

693 **Table 1** – deep-DNAseq identifies CHIP mutations in atherosclerotic plaques and left  
694 ventricular myocardium

695

696 **Figures**

697 **Figure 1** – Central illustration highlighting most relevant novel findings

698 **Figure 2** – mutaFISH™ visualizes CHIP-mutated leukocytes in human plaques

699 **Figure 3** – RNAseq of macrophages (TET2-CHIP vs non mutation carriers)

700 **Figure 4** – RNAseq of macrophages (ASXL1-CHIP vs non mutation carriers)

701

702 **Supplement**

703 **Supplemental Table 1** – List of CHIP mutations in MISSION

704 **Supplemental Table 2** – List of CHIP mutations in STARNET

705 **Supplemental Table 3** – STARNET patient characteristics TET2 macrophages

706 **Supplemental Table 4** – STARNET patient characteristics ASXL1 macrophages

707 **Supplemental Figure 1** – VAF and distribution of CHIP mutations in MISSION

708 **Supplemental Figure 2** – Deep-DNAseq identifies CHIP mutations in atherosclerotic  
709 coronary and carotid samples, and left ventricular myocardium

710 **Supplemental Figure 3** – Overview plaque of interest – different stainings


711 **Supplemental Figure 4** – Visualization of CD68<sup>+</sup> CHIP mutated macrophage

712 **Supplemental Figure 5** – DNMT3A CHIP mutation (c.2245C>T) in human atherosclerotic  
713 plaque

714 **Protocol** – adapted mutaFISH™ protocol

715 **Table 1** – This study provides evidence that CHIP-mutated leukocytes have the potential to  
 716 invade human atherosclerotic plaques in coronary and carotid arteries, and heart muscle from  
 717 peripheral blood. Out of 25 unique CHIP mutations (identified in whole blood), 18 mutations  
 718 (shown) were identified in at least one corresponding tissue of interest. Tissue sequencing of  
 719 CHIP mutation carriers revealed that identical CHIP mutations were identified in the  
 720 corresponding coronary artery (n=13), carotid artery (n=10) and left ventricular heart muscle  
 721 (n=4) (right). Provided are mutations on DNA level and variant allele frequency (VAF) in %.

<b>CHIP-affected gene</b> (mutation)	<b>Whole Blood</b> (VAF in %)	<b>Coronary</b> (VAF in %)	<b>Carotid</b> (VAF in %)	<b>Heart Muscle</b> (VAF in %)
<b>ASXL1</b> (c.1772dup)	5.2	1.2	0	0
<b>CBL</b> (c.1211G>A)	9.1	2.2	0	0
<b>DNMT3A</b> (c.1628G>C)	21.6	0	5.4	0
<b>DNMT3A</b> (c.976C>T)	20.5	0	2.4	0
<b>DNMT3A</b> (c.2333T>G)	6.5	2.5	0	0
<b>DNMT3A</b> (c.2245C>T)	5.6	1.5	0	1.5
<b>DNMT3A</b> (c.1726_1729delinsC)	22.6	5.9	5.8	0
<b>DNMT3A</b> (c.1969G>A)	5.3	1.0	1.1	0
<b>DNMT3A</b> (c.2204A>G)	11.3	0	2.5	0
<b>DNMT3A</b> (c.2104G>T)	11.8	1.4	2.7	0
<b>PPM1D</b> (c.1535del)	0.7	0	2.0	0
<b>PPM1D</b> (c.1535del)	0.9	1.8	0	0
<b>SMC3</b> (c.3598G>A)	6.0	1.1	0	1.0
<b>TET2</b> (c.2839C>T)	19.2	4.0	5.1	0
<b>TET2</b> (c.4193T>G)	6.4	2.1	2.1	0
<b>TET2</b> (c.1219del)	27.7	4.4	0	2.0
<b>TET2</b> (c.4546C>T)	29.7	5.1	0	2.6
<b>TET2</b> (c.5454_5458del)	9.8	0	2.1	0



722

723

724

725

726

727

728

729

730

731


732

733

734

735


**Figure 1.** Central illustration – important novel findings from this study. **Left panel:** Over 300 CHIP mutation carriers from the Munich cardiovascular Studies biObaNk (MISSION) and the Stockholm-Tartu Atherosclerosis Reverse Networks Engineering Task (STARNET) studies were evaluated. **Upper panel:** In our study, we confirmed blood derived CHIP mutations in human atherosclerotic plaques of coronary artery, carotids and heart muscle on DNA level. **Middle panel:** For the first time we were able to visualize macrophages with specific *DNMT3A* CHIP mutations using mutaFISH™ at single cell resolution in human atherosclerotic plaques. Enrichment of CHIP mutated cells in human plaques was confirmed. **Lower panel:** Previously unknown pro-atherosclerotic alterations in gene expression of CHIP mutated macrophages at the level of regulatory key-drivers, pathways, networks, and modules with relevance for CAD progression were identified. ASXL1: ASXL Transcriptional Regulator 1; CAD: Coronary artery disease; CHIP: Clonal hematopoiesis of indeterminate potential; DNMT3A: DNA Methyltransferase 3 Alpha; HSC: hematopoietic stem cell; mutaFISH: mutation-specific Fluorescence In Situ Hybridization; TET2: Tet Methylcytosine Dioxygenase 2.



736


737 **Figure 2** – CHIP-mutated cells have the potential to invade from the peripheral blood into human atherosclerotic lesions. mutaFISH™ allowed detection of single  
 738 nucleotide exchanges at the RNA level in single cells. Staining for a specific DNMT3A mutation (mut) and wild type (wt) at the RNA level was performed *in situ* in  
 739 advanced atherosclerotic plaques of human FFPE coronary tissue. **Left panel:** merged overview of an advanced atherosclerotic plaque. Red boxes highlight areas  
 740 of interest enlarged in the following panels. **Middle panel:** CHIP-affected leukocytes were identified in the inflammatory shoulder regions of human atherosclerotic  
 741 plaque (white arrow). **Right panel:** The DNMT3A mutation c.2333G>T was detected on single cell resolution via the green signal, the DNMT3A wild type via the  
 742 red signal and the cell nuclei (DAPI) via the blue signal. DAPI: 4',6-Diamidin-2-phenylindole; EEL: external elastic lamina; FFPE: formalin-fixed paraffin embedded;  
 743 IEL: internal elastic lamina; LU: lumen; mutaFISH: mutation-specific Fluorescence In Situ Hybridization.





744

745 **Figure 3** – Differentially expressed genes in TET2 CHIP mutation carriers (n=3) versus age and sex matched non-mutation controls (n=21) were enriched in  
 746 darkgreen module in STARNET macrophage RNAseq data. **Left upper panel:** Volcano plot of differentially expressed genes between TET2 CHIP mutation carriers  
 747 versus age and sex matched non-mutation controls in STARNET CAD cases. Differentially expressed genes were highlighted in lightblue. Top upregulated and  
 748 downregulated genes with the smallest p-values or with the biggest log2 fold changes were labeled with gene names. Differentially expressed genes that overlap  
 749 with darkgreen module genes were highlighted in darkgreen. **Left bottom panel:** Top 10 enriched gene ontologies for differentially expressed genes in TET2 CHIP  
 750 mutation carriers versus non-mutation controls. Bonferroni corrected p<0.05 was considered statistically significant. **Right upper panel:** Visualization of darkgreen  
 751 module inferred from STARNET macrophage RNAseq data. Top key drivers were highlighted in yellowgreen. **Right bottom panel:** Dot plot indicating the  
 752 association of darkgreen module genes with clinical traits. P-value <0.05 (-log<sub>10</sub>(p) >1.3, cut off was indicated by vertical red line) is considered statistically  
 753 significant.GO: Gene Ontology; BP: biological pathway; CC: cellular component; MF: molecular function.



754

755 **Figure 4** – Differentially expressed genes in ASXL1 CHIP mutation carriers (n=3) versus age and sex matched non-mutation controls (n=27) were enriched in  
 756 black module in STARNET macrophage RNAseq data. **Left upper panel:** Volcano plot of differentially expressed genes (DEGs) between ASXL1 CHIP mutation  
 757 carriers versus age and sex matched non-mutation controls in STARNET CAD cases. Differentially expressed genes were highlighted in pink. Top upregulated and  
 758 downregulated genes with the smallest p-values or with the biggest log2 fold changes were labeled with gene names. Differentially expressed genes that overlap  
 759 with black module genes were highlighted in black. **Left bottom panel:** Top 10 enriched gene ontology (GO) terms for differentially expressed genes in ASXL1  
 760 CHIP mutation carriers versus non-mutation controls. Bonferroni corrected  $p < 0.05$  was considered statistically significant. **Right upper panel:** Visualization of black  
 761 module inferred from STARNET macrophage RNAseq data. Top key drivers were highlighted in pink. **Right bottom panel:** Dot plot for the association of black  
 762 module genes with clinical traits. P-value  $< 0.05$  ( $-\log_{10}(p) > 1.3$ , cut off was indicated by vertical red line) is considered statistically significant. GO: Gene Ontology;  
 763 BP: biological pathway; CC: cellular component; MF: molecular function.